We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Effects of a combination of disopyramide and mexiletine on the anterograde accessory pathway conduction in patients with Wolff-Parkinson-White Syndrome.
- Authors
SHIMIZU, W.; OHE, T.; KURITA, T.; TAKAKI, H.; AIHARA, N.; KAMAKURA, S.; MATSUHISA, M.; SHIMOMURA, K.
- Abstract
In order to evaluate the electrophysiological effects of the combined administration of disopyramide and mexiletine on anterograde accessory pathway conduction, we studied 11 patients with Wolff-Parkinson- White (WPW) syndrome. Disopyramide was first infused intravenously at 1 mg kgfor 5 min followed by a continuous infusion at 0.025 mg kg min. After the infusion rate of disopyramide was decreased to 0.004 mg kg mm to maintain a lower serum concentration, mexiletine was infused at 2mg kg for 5 min followed by a continuous infusion at 0.008mg kg min (protocol 1). The shortest atrial paced cycle length with 1:1 anterograde accessory pathway conduction (shortest CL with 1:1) and the anterograde effective refractory period of the accessory pathway (ERP) were measured: (1) before drug administration, (2) after disopyramide was given alone, and (3) after disopyramide and mexiletine were combined at lower concentrations. The same protocol was repeated with the order of drug administration reversed (mexiletine followed by disopyramide) in all patients (protocol 2). Both disopyramide and mexiletine lengthened the shortest CL with 1:1 and the ERP to the same degree. The combination of disopyramide and mexiletine at lower concentrations further lengthened the shortest CL with 1:1. It was longer than with disopyramide (protocol 1) or mexiletine (protocol 2) alone [protocol 1. 412 ± 169 ms (combination) vs 356 ± 117 ms (disopyramide); P <0.05, protocol 2: 409 ± 166 ms (combination) vs 355 . 119 ms (mexiletine); P <0.01]. The combination lengthened the ERP more than did mexiletine alone [332 ± 73 ms (combination) vs 299 ± 42 ms (mexiletine): p <0.05]. Moreover, it lengthened the shortest and the mean RR interval during atrial fibrillation more than disopyramide or mexiletine did alone in alifour patients in whom atrial fibrillation was induced. We conclude that a combination of disopyramide and mexiletine has at least additive effects on anterograde accessory pathway conduction in patients with WPW syndrome.
- Publication
European Heart Journal, 1992, Vol 13, Issue 2, p261
- ISSN
0195-668X
- Publication type
Article
- DOI
10.1093/oxfordjournals.eurheartj.a060157